- Home
- RARE
as 10-22-2025 3:52pm EST
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | 3.1B | IPO Year: | 2014 |
| Target Price: | $87.69 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.81 - $56.38 | Next Earning Date: | 11-03-2025 |
| Revenue: | $610,159,000 | Revenue Growth: | 26.77% |
| Revenue Growth (this year): | 19.72% | Revenue Growth (next year): | 23.29% |
Stock Insider Trading Activity of Ultragenyx Pharmaceutical Inc. (RARE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Horn Howard | RARE | Chief Financial Officer | Oct 13 '25 | Sell | $31.51 | 7,942 | $250,252.42 | 98,227 | |
| Parschauer Karah Herdman | RARE | EVP and Chief Legal Officer | Sep 12 '25 | Sell | $31.17 | 2,450 | $76,366.50 | 73,271 | |
| Huizenga Theodore Alan | RARE | SVP, Chief Accounting Officer | Sep 5 '25 | Sell | $31.39 | 84 | $2,636.76 | 50,306 |
Latest Ultragenyx Pharmaceutical Inc. News
RARE Breaking Stock News: Dive into RARE Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength?
GlobeNewswire
19 days ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
19 days ago
Ultragenyx Pharmaceutical (RARE): Valuation Perspectives Following Regulatory Milestones and Pipeline Progress
Simply Wall St.
20 days ago
How Might Ultragenyx (RARE) Leverage Dealmaking Expertise to Shape Its Long-Term Growth Strategy?
Insider Monkey
20 days ago
Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline
MT Newswires
22 days ago
Ultragenyx Names Eric Olson as Chief Business Officer
GlobeNewswire
22 days ago
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
Zacks
a month ago
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
Compare RARE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RARE Ultragenyx Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.